<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576626</url>
  </required_header>
  <id_info>
    <org_study_id>NL5250604215</org_study_id>
    <nct_id>NCT02576626</nct_id>
  </id_info>
  <brief_title>Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD</brief_title>
  <acronym>ULT01</acronym>
  <official_title>The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wouter H. van Geffen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groningen Research Institute for Asthma and COPD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Inhaled bronchodilators, beta-2-agonist or anticholinergic or combinations, can be delivered
      by several types of devices: dry powder (DPI), pressurized metered dose inhalers (pMDI), and
      wet nebulizers. Wet nebulization is available for short-acting bronchodilators only, is
      cumbersome, and, importantly, has never been scientifically been proven to be more
      efficacious than delivery by the other two methods. Yet many patients are happy with wet
      nebulization and in many clinics this administration method prevails. The investigators
      believe that combined long-acting bronchodilators, are more efficacious than combined short
      acting bronchodilators per nebulizers.

      Objective:

      To test the hypothesis that: The combination of the two long-acting bronchodilators
      indacaterol and glycopyrronium by dry powder inhalation confers a superior improvement
      compared to nebulisation with ipratropium/salbutamol, when administered as single dose in
      patients with stable state chronic obstructive pulmonary disease (COPD).

      Study design: Investigator initiated, randomised, active controlled, cross-over double-blind
      (and therefore double-dummy), study comparing the effects of single dose
      indacaterol/glycopyrronium 110/50 Breezhaler® versus single dose ipratropium/salbutamol
      nebulisation in patients with COPD in stable state Study population: Patients visiting the
      outpatient clinics or from general practitioner (GP) practices with COPD GOLD stage A-D, and
      (FEV1) post-bronchodilator FEV1/ forced vital capacity (FVC) &lt; 70%; post-br FEV1 &lt; 80%pred.
      Intervention The investigators will compare the effects of single dose
      indacaterol/glycopyrronium 110/50 Breezhaler® versus single dose ipratropium/salbutamol
      nebulisation in patients with COPD in stable state

      Main study parameters/endpoints:

      Area under the curve (AUC) from 0 to 6 hours of FEV1 with indacaterol and glycopyrronium,
      compared to nebulisation with ipratropium/salbutamol

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness:

      This study has no specific benefits for the participating patients. The study also has no
      major risks. Minor risks for participants after a single dosis can be throat irritation,
      cough, headache and dizziness, sinus tachycardia. The combination of treatments with
      β2-agonist bronchodilators and anticholinergic bronchodilators have been used in daily
      practice for many years in many countries and they are often prescribed both in COPD. Both
      indacaterol/glycopyrronium and ipratropium/salbutamol are approved for COPD treatment in the
      Netherlands
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of FEV1</measure>
    <time_frame>from 0 to 6 hours</time_frame>
    <description>Area under the curve (AUC) from 0 to 6 hours of FEV1 with indacaterol and glycopyrronium, compared to nebulisation with ipratropium/salbutamol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Borg dyspnea score at 30 min</measure>
    <time_frame>30 min up to 360 minutes</time_frame>
    <description>1. Change in Borg dyspnea score at 30 min: change in Borg score at other time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching the minimal clinically important difference (MCID) at all time points</measure>
    <time_frame>all time points (15, 30, 60, 120 240 and 360 min)</time_frame>
    <description>proportion of patients reaching the MCID at all time points (15, 30, 60, 120 240 and 360 min) (1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in level of hyperinflation (by IC measurement)</measure>
    <time_frame>all time points (15, 30, 60, 120 240 and 360 min)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to FEV1 increase of 100 ml</measure>
    <time_frame>all time points (15, 30, 60, 120 240 and 360 min)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak effect of FEV1</measure>
    <time_frame>from 0 to 6 hours</time_frame>
    <description>Maximum FEV1 per group, calculated using the best FEV1 per participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak of FEV1</measure>
    <time_frame>all time points (15, 30, 60, 120 240 and 360 min)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>at all time points (15, 30, 60, 120 240 and 360 min)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants reaching a difference of 100 ml of inspiratory capacity (IC)</measure>
    <time_frame>Time Frame: all time points (15, 30, 60, 120 240 and 360 min)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.
Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indacaterol/glycopyrronium 110/50 Breezhaler®</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Ultibro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo by Breezhaler®</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Combivent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo by nebulisation</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. COPD, post-bronchodilator FEV1/FVC &lt; 70%; post-br FEV1 &lt; 80%pred

          2. Active mastery of Dutch

          3. Written informed consent

          4. At least 40 years old

          5. Participants must be able to understand and complete protocol requirements,
             Instructions, and questionnaires provided in Dutch

        Exclusion Criteria:

          1. Non invasive ventilation

          2. Saturation by pulse oxymetry &lt;88%

          3. Documented history of asthma

          4. Instable cardiac disease within 6 months.

          5. Known long corrected QT interval (QTC) syndrome

          6. Known estimated Glomerular Filtration Rate (EGFR) ( &lt;30 ml/min *1,73m2

          7. Exacerbations of COPD or change of medication for COPD in the last 6 weeks prior to
             inclusion

          8. Allergic reaction or intolerance for a substance used in one of the products or
             atropine or atropine derived substances

          9. Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huib AM Kerstjens, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groningen Research Institute for Asthma and COPD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wouter H van Geffen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Centre Leeuwarden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Groningen Research Institute for Asthma and COPD</investigator_affiliation>
    <investigator_full_name>Wouter H. van Geffen</investigator_full_name>
    <investigator_title>Arts onderzoeker</investigator_title>
  </responsible_party>
  <keyword>Nebulizer</keyword>
  <keyword>DPI</keyword>
  <keyword>COPD</keyword>
  <keyword>indacaterol</keyword>
  <keyword>ipratropium</keyword>
  <keyword>glycopyrronium</keyword>
  <keyword>salbutamol</keyword>
  <keyword>Breezhaler</keyword>
  <keyword>Nebuliser</keyword>
  <keyword>Hyperinflation</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>SABA</keyword>
  <keyword>short-acting muscarinic antagonists (SAMA)</keyword>
  <keyword>long-acting beta2-agonist (LABA)</keyword>
  <keyword>LAMA</keyword>
  <keyword>FEV1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

